gc301
Pompe Disease (Late-onset)
GeneCradle Incgene_therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Pompe Disease (Late-onset) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alglucosidase Alfa Erasmus Medical Center | Phase 4 | BBB |
Cipaglucosidase Alfa-ATGA Amicus Therapeutics | Phase 3 | BB |
Avalglucosidase Alfa Iris Plug | Phase 4 | BB |
Miglustat Amicus Therapeutics | Phase 3 | B |
at2221 Amicus Therapeutics | Phase 3 | B |
View all 13 →
Same molecule, other indications
gc301 is also rated in:
glycogen storage disease due to acid maltase deficiency, infantile onsetDormant
CCC
Indicative ·
48 / 100
View asset →glycogen storage disease due to acid maltase deficiency, infantile onsetDormant
CCC
Indicative ·
48 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →